• Personalis’ third-quarter 2026 net loss widened 56% year over year to $33.8 million.
• Revenue rose 77% to $25.6 million, driven by growth in clinical testing, population sequencing and pharma testing services.
• Clinical test revenue increased to $4.4 million, while clinical test volume nearly tripled to 13,157.
• The company launched NeXT Personal Real-Time Variant Tracker to identify clinically relevant resistance and therapeutically targetable variants over time.
• Following its July 20 merger agreement with Tempus AI, the company will no longer provide financial guidance or hold quarterly earnings calls.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Personalis Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20261104890700) on November 04, 2026, and is solely responsible for the information contained therein.